Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study

PURPOSE: The OVA-YOND study is the first prospective, non-interventional trial designed to evaluate trabectedin (1.1 mg/m(2)) plus PLD (30 mg/m(2)) in patients with platinum-sensitive recurrent ovarian cancer (ROC), given according to the marketing authorization in real-life clinical practice across...

Descripción completa

Detalles Bibliográficos
Autores principales: Runnebaum, Ingo B., Reichert, Dietmar, Ringsdorf, Uta, Kuther, Markus, Hesse, Tobias, Sehouli, Jalid, Wimberger, Pauline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948298/
https://www.ncbi.nlm.nih.gov/pubmed/29623421
http://dx.doi.org/10.1007/s00432-018-2637-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948298/
https://www.ncbi.nlm.nih.gov/pubmed/29623421
http://dx.doi.org/10.1007/s00432-018-2637-1

Ejemplares similares